New and emerging approaches to treat psychiatric disorders

[1]  M. Mennes,et al.  The effects of transient receptor potential cation channel inhibition by BI 1358894 on cortico-limbic brain reactivity to negative emotional stimuli in major depressive disorder , 2022, European Neuropsychopharmacology.

[2]  K. Deisseroth,et al.  Maturation and circuit integration of transplanted human cortical organoids , 2022, Nature.

[3]  T. Friede,et al.  Effect of Minocycline on Depressive Symptoms in Patients With Treatment-Resistant Depression , 2022, JAMA network open.

[4]  P. Stanton,et al.  Zelquistinel Is an Orally Bioavailable Novel NMDA Receptor Allosteric Modulator That Exhibits Rapid and Sustained Antidepressant-Like Effects , 2022, The international journal of neuropsychopharmacology.

[5]  D. Iosifescu,et al.  Effect of AXS-05 (Dextromethorphan-Bupropion) in Major Depressive Disorder: A Randomized Double-Blind Controlled Trial. , 2022, The American journal of psychiatry.

[6]  Johannes Björkstrand,et al.  Preliminary Evidence of Efficacy and Target Engagement of Pramipexole in Anhedonic Depression , 2022, Biological Psychiatry.

[7]  Michael F. Green,et al.  Mapping genomic loci implicates genes and synaptic biology in schizophrenia , 2022, Nature.

[8]  Richard E. Daws,et al.  Increased global integration in the brain after psilocybin therapy for depression , 2022, Nature Medicine.

[9]  J. Parvizi,et al.  Complex negative emotions induced by electrical stimulation of the human hypothalamus , 2022, Brain Stimulation.

[10]  M. Solmi,et al.  Efficacy of neurostimulation across mental disorders: systematic review and meta-analysis of 208 randomized controlled trials , 2022, Molecular Psychiatry.

[11]  Timothy O. Laumann,et al.  Reproducible brain-wide association studies require thousands of individuals , 2022, Nature.

[12]  Ming-Hu Han,et al.  The Potential of KCNQ Potassium Channel Openers as Novel Antidepressants , 2022, CNS Drugs.

[13]  Mascha van 't Wout-Frank,et al.  Low Intensity Focused Ultrasound for Non-invasive and Reversible Deep Brain Neuromodulation—A Paradigm Shift in Psychiatric Research , 2022, Frontiers in Psychiatry.

[14]  J. Ioannidis,et al.  The efficacy of psychotherapies and pharmacotherapies for mental disorders in adults: an umbrella review and meta‐analytic evaluation of recent meta‐analyses , 2022, World psychiatry : official journal of the World Psychiatric Association.

[15]  E. Bullmore,et al.  Immune targets for therapeutic development in depression: towards precision medicine , 2022, Nature reviews. Drug discovery.

[16]  Qiuwen Li,et al.  A single intravenous administration of a sub-anesthetic ketamine dose during the perioperative period of cesarean section for preventing postpartum depression: A meta-analysis , 2022, Psychiatry Research.

[17]  A. Leaver,et al.  Parsing the Network Mechanisms of Electroconvulsive Therapy , 2021, Biological Psychiatry.

[18]  C. McIntyre,et al.  Deep Brain Stimulation for Depression Informed by Intracranial Recordings , 2021, Biological Psychiatry.

[19]  Cherise R. Chin Fatt,et al.  Patterns of Pretreatment Reward Task Brain Activation Predict Individual Antidepressant Response: Key Results From the EMBARC Randomized Clinical Trial , 2021, Biological Psychiatry.

[20]  Arielle S. Keller,et al.  Mapping Neural Circuit Biotypes to Symptoms and Behavioral Dimensions of Depression and Anxiety , 2021, Biological Psychiatry.

[21]  Francis X. Shen,et al.  An Ethics Checklist for Digital Health Research in Psychiatry: Viewpoint , 2021, Journal of medical Internet research.

[22]  Lynnette A. Averill,et al.  Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial , 2021, Neuropsychopharmacology.

[23]  K. Narr,et al.  Default mode network connectivity and treatment response in geriatric depression , 2021, Brain and behavior.

[24]  R. N. Spreng,et al.  Serotonergic psychedelic drugs LSD and psilocybin reduce the hierarchical differentiation of unimodal and transmodal cortex , 2020, NeuroImage.

[25]  Jeffrey F. Cohn,et al.  Facial Action Units and Head Dynamics in Longitudinal Interviews Reveal OCD and Depression severity and DBS Energy , 2021, 2021 16th IEEE International Conference on Automatic Face and Gesture Recognition (FG 2021).

[26]  Nelson B Rodrigues,et al.  Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression , 2021, CNS Drugs.

[27]  D. E. Olson,et al.  Psychedelics and Other Psychoplastogens for Treating Mental Illness , 2021, Frontiers in Psychiatry.

[28]  Heather E. Dawes,et al.  Closed-loop neuromodulation in an individual with treatment-resistant depression , 2021, Nature Medicine.

[29]  A. Kaye,et al.  Brexanolone, a GABAA Modulator, in the Treatment of Postpartum Depression in Adults: A Comprehensive Review , 2021, Frontiers in Psychiatry.

[30]  P. Brambilla,et al.  Connectivity changes in major depressive disorder after rTMS: a review of functional and structural connectivity data , 2021, Epidemiology and Psychiatric Sciences.

[31]  N. Roberts,et al.  Shared and distinct brain fMRI response during performance of working memory tasks in adult patients with schizophrenia and major depressive disorder , 2021, Human brain mapping.

[32]  M. Thase,et al.  Treatment resistance in psychiatry: state of the art and new directions , 2021, Molecular Psychiatry.

[33]  M. Treadway,et al.  Aiding and Abetting Anhedonia: Impact of Inflammation on the Brain and Pharmacological Implications , 2021, Pharmacological Reviews.

[34]  Kara A. Johnson,et al.  Connectomic Deep Brain Stimulation for Obsessive-Compulsive Disorder , 2021, Biological Psychiatry.

[35]  A. Vandenberg,et al.  Review of Allopregnanolone Agonist Therapy for the Treatment of Depressive Disorders , 2021, Drug design, development and therapy.

[36]  H. Gunduz-Bruce,et al.  Effect of Zuranolone vs Placebo in Postpartum Depression , 2021, JAMA psychiatry.

[37]  C. N. Lessov-Schlaggar,et al.  A phase 2 trial of inhaled nitrous oxide for treatment-resistant major depression , 2021, Science Translational Medicine.

[38]  M. Niciu,et al.  Biomarkers of ketamine’s antidepressant effect: a clinical review of genetics, functional connectivity, and neurophysiology , 2021, Chronic stress.

[39]  Andrew H. Miller,et al.  Kynurenines increase MRS metabolites in basal ganglia and decrease resting-state connectivity in frontostriatal reward circuitry in depression , 2021, Translational Psychiatry.

[40]  C. Zarate,et al.  Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status , 2021, CNS Drugs.

[41]  D. Nutt,et al.  Trial of Psilocybin versus Escitalopram for Depression. , 2021, The New England journal of medicine.

[42]  K. Narr,et al.  Depression treatment response to ketamine: sex-specific role of interleukin-8, but not other inflammatory markers , 2021, Translational Psychiatry.

[43]  T. Robbins,et al.  Time to re-engage psychiatric drug discovery by strengthening confidence in preclinical psychopharmacology , 2021, Psychopharmacology.

[44]  E. Stern,et al.  Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial. , 2021, The American journal of psychiatry.

[45]  A. Egerton,et al.  Peripheral immune markers and antipsychotic non-response in psychosis , 2021, Schizophrenia Research.

[46]  M. M. Chan,et al.  The neurobiology of prefrontal transcranial direct current stimulation (tDCS) in promoting brain plasticity: A systematic review and meta-analyses of human and rodent studies , 2021, Neuroscience & Biobehavioral Reviews.

[47]  R. Keefe,et al.  Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study. , 2021, The lancet. Psychiatry.

[48]  Pasha A Davoudian,et al.  Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo , 2021, Neuron.

[49]  E. Chang,et al.  State-dependent responses to intracranial brain stimulation in a patient with depression , 2021, Nature Medicine.

[50]  N. Galvão-Coelho,et al.  Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants , 2021, Psychopharmacology.

[51]  S. Rossi,et al.  Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines , 2020, Clinical Neurophysiology.

[52]  E. Stern,et al.  Impact of the KCNQ 2 / 3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression : Results FromaRandomizedControlledTrial , 2021 .

[53]  S. Postnova,et al.  Progress in modelling of brain dynamics during anaesthesia and the role of sleep-wake circuitry. , 2020, Biochemical pharmacology.

[54]  Nelson B Rodrigues,et al.  The effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysis. , 2020, Journal of affective disorders.

[55]  E. Waltz.  Green light for deep brain stimulator incorporating neurofeedback , 2020, Nature Biotechnology.

[56]  W. Drevets,et al.  Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II) , 2020, The international journal of neuropsychopharmacology.

[57]  Matthew J. Johnson,et al.  Revealing the structure of pharmacobehavioral space through Motion Sequencing , 2020, Nature Neuroscience.

[58]  Cory S. Inman,et al.  Human amygdala stimulation effects on emotion physiology and emotional experience , 2020, Neuropsychologia.

[59]  D. Nutt,et al.  The Current Status of Psychedelics in Psychiatry. , 2020, JAMA psychiatry.

[60]  B. Strange,et al.  A unified connectomic target for deep brain stimulation in obsessive-compulsive disorder , 2020, Nature Communications.

[61]  A. Young,et al.  Minocycline and celecoxib as adjunctive treatments for bipolar depression: a multicentre, factorial design randomised controlled trial. , 2020, The lancet. Psychiatry.

[62]  Zhihao Li,et al.  Protein and gene markers of metabolic dysfunction and inflammation together associate with functional connectivity in reward and motor circuits in depression , 2020, Brain, Behavior, and Immunity.

[63]  M. Weissman,et al.  Pretreatment Reward Sensitivity and Frontostriatal Resting-State Functional Connectivity Are Associated With Response to Bupropion After Sertraline Nonresponse , 2020, Biological Psychiatry.

[64]  M. Clark,et al.  Results from a randomized controlled trial testing StressProffen; an application‐based stress‐management intervention for cancer survivors , 2020, Cancer medicine.

[65]  J. Calabrese,et al.  A randomized proof-of-mechanism trial applying the ‘fast-fail’ approach to evaluating κ-opioid antagonism as a treatment for anhedonia , 2020, Nature Network Boston.

[66]  T. Sakurai,et al.  Orexin as a modulator of fear-related behavior: Hypothalamic control of noradrenaline circuit , 2020, Brain Research.

[67]  Wei Jiang,et al.  Immune biomarkers alterations in post-traumatic stress disorder: A systematic review and meta-analysis. , 2020, Journal of affective disorders.

[68]  Joseph L. Sanguinetti,et al.  Transcranial Focused Ultrasound to the Right Prefrontal Cortex Improves Mood and Alters Functional Connectivity in Humans , 2020, Frontiers in Human Neuroscience.

[69]  O. Howes,et al.  Inflammatory markers in depression: A meta-analysis of mean differences and variability in 5,166 patients and 5,083 controls , 2020, Brain, Behavior, and Immunity.

[70]  Simon B Eickhoff,et al.  Multimodal Abnormalities of Brain Structure and Function in Major Depressive Disorder: A Meta-Analysis of Neuroimaging Studies. , 2020, The American journal of psychiatry.

[71]  Michael Inzlicht,et al.  Why Are Self-Report and Behavioral Measures Weakly Correlated? , 2020, Trends in Cognitive Sciences.

[72]  Heather E. Dawes,et al.  Distributed Subnetworks of Depression Defined by Direct Intracranial Neurophysiology , 2020, bioRxiv.

[73]  Jenna M. Reinen,et al.  Baseline reward processing and ventrostriatal dopamine function are associated with pramipexole response in depression. , 2020, Brain : a journal of neurology.

[74]  A. Young,et al.  Cholinergic Modulation of Disorder-Relevant Neural Circuits in Generalized Anxiety Disorder , 2020, Biological Psychiatry.

[75]  E. Stern,et al.  Ketamine normalizes subgenual cingulate cortex hyper-activity in depression , 2020, Neuropsychopharmacology.

[76]  S. Rossi,et al.  Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014–2018) , 2019, Clinical Neurophysiology.

[77]  D. Araujo,et al.  Subacute effects of the psychedelic ayahuasca on the salience and default mode networks , 2019, Journal of psychopharmacology.

[78]  Matthew W. Mosconi,et al.  Large-Scale Exome Sequencing Study Implicates Both Developmental and Functional Changes in the Neurobiology of Autism , 2019, Cell.

[79]  Melissa J. Green,et al.  The genetics of the mood disorder spectrum: genome-wide association analyses of over 185,000 cases and 439,000 controls , 2018, bioRxiv.

[80]  Dennis J. Dacarett-Galeano,et al.  Brexanolone: A Novel Therapeutic in the Treatment of Postpartum Depression , 2019, American Journal of Psychiatry Residents' Journal.

[81]  Philip D. Harvey,et al.  GPS mobility as a digital biomarker of negative symptoms in schizophrenia: a case control study , 2019, npj Digital Medicine.

[82]  W. Drevets,et al.  The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder , 2019, Translational Psychiatry.

[83]  Xiang Li,et al.  Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. , 2019, JAMA psychiatry.

[84]  anonymous,et al.  Comprehensive review , 2019 .

[85]  I. Sommer,et al.  An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis , 2019, Psychological Medicine.

[86]  C. Ross,et al.  Research Domain Criteria: Strengths, Weaknesses, and Potential Alternatives for Future Psychiatric Research , 2019, Molecular Neuropsychiatry.

[87]  Alicia R. Martin,et al.  Predicting Polygenic Risk of Psychiatric Disorders , 2019, Biological Psychiatry.

[88]  F. De Crescenzo,et al.  Pramipexole in the treatment of unipolar and bipolar depression. A systematic review and meta‐analysis , 2019, Acta psychiatrica Scandinavica.

[89]  R. Temple,et al.  Esketamine for Treatment-Resistant Depression - First FDA-Approved Antidepressant in a New Class. , 2019, The New England journal of medicine.

[90]  R. Shelton,et al.  Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. , 2019, The American journal of psychiatry.

[91]  Jeffrey F. Cohn,et al.  AFAR: A Deep Learning Based Tool for Automated Facial Affect Recognition , 2019, 2019 14th IEEE International Conference on Automatic Face & Gesture Recognition (FG 2019).

[92]  O. Mors,et al.  Efficacy of anti‐inflammatory treatment on major depressive disorder or depressive symptoms: meta‐analysis of clinical trials , 2019, Acta psychiatrica Scandinavica.

[93]  Cory S. Inman,et al.  Autonomic arousal elicited by subcallosal cingulate stimulation is explained by white matter connectivity , 2019, Brain Stimulation.

[94]  Frederick S. Barrett,et al.  Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function , 2019, Pharmacology & therapeutics.

[95]  N. Šestan,et al.  Restoration of brain circulation and cellular functions hours post-mortem , 2019, Nature.

[96]  A. Schatzberg,et al.  Stanford accelerated intelligent neuromodulation therapy for treatment-resistant depression (SAINT-TRD) , 2019, Brain Stimulation.

[97]  S. Wilkinson,et al.  A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems. , 2019, Drug discovery today.

[98]  H. Bergman,et al.  Deep brain stimulation: current challenges and future directions , 2019, Nature Reviews Neurology.

[99]  S. Borgwardt,et al.  Neuroimaging of chronic MDMA (“ecstasy”) effects: A meta-analysis of the literature , 2019, Neuroscience & Biobehavioral Reviews.

[100]  Conor Liston,et al.  Functional and Optogenetic Approaches to Discovering Stable Subtype-Specific Circuit Mechanisms in Depression , 2018, bioRxiv.

[101]  Deanna L. Wallace,et al.  Direct Electrical Stimulation of Lateral Orbitofrontal Cortex Acutely Improves Mood in Individuals with Symptoms of Depression , 2018, Current Biology.

[102]  C. Fales,et al.  Resting-state functional connectivity, cortical GABA, and neuroactive steroids in peripartum and peripartum depressed women: a functional magnetic resonance imaging and spectroscopy study , 2018, Neuropsychopharmacology.

[103]  Jeffrey F. Cohn,et al.  Automated Affect Detection in Deep Brain Stimulation for Obsessive-Compulsive Disorder: A Pilot Study , 2018, ICMI.

[104]  Jonathan Kipnis,et al.  The Meningeal Lymphatic System: A New Player in Neurophysiology , 2018, Neuron.

[105]  Dan J Stein,et al.  The Lancet Commission on global mental health and sustainable development , 2018, The Lancet.

[106]  Zhihao Li,et al.  Inflammation negatively correlates with amygdala-ventromedial prefrontal functional connectivity in association with anxiety in patients with depression: Preliminary results , 2018, Brain, Behavior, and Immunity.

[107]  Zhihao Li,et al.  Increased inflammation and brain glutamate define a subtype of depression with decreased regional homogeneity, impaired network integrity, and anhedonia , 2018, Translational Psychiatry.

[108]  A. Ferrari,et al.  The global burden of mental and substance use disorders , 2018, Oxford Textbook of Public Mental Health.

[109]  M. Nitsche,et al.  Physiology of Transcranial Direct Current Stimulation , 2018, The journal of ECT.

[110]  D. Goldsmith,et al.  Antidepressant treatment resistance is associated with increased inflammatory markers in patients with major depressive disorder , 2018, Psychoneuroendocrinology.

[111]  Francesco Cardinale,et al.  Motor and emotional behaviours elicited by electrical stimulation of the human cingulate cortex , 2018, Brain : a journal of neurology.

[112]  S. Rauch,et al.  Digital devices and continuous telemetry: opportunities for aligning psychiatry and neuroscience , 2018, Neuropsychopharmacology.

[113]  R. DeRubeis,et al.  Personalized prediction of antidepressant v. placebo response: evidence from the EMBARC study , 2018, Psychological Medicine.

[114]  Lari M. Koponen,et al.  Multi-locus transcranial magnetic stimulation—theory and implementation , 2018, Brain Stimulation.

[115]  D. Goldsmith,et al.  What does plasma CRP tell us about peripheral and central inflammation in depression? , 2018, Molecular Psychiatry.

[116]  D. E. Olson,et al.  Psychedelics Promote Structural and Functional Neural Plasticity , 2018, Cell reports.

[117]  Hussein N. Rubaiy,et al.  Remarkable Progress with Small-Molecule Modulation of TRPC1/4/5 Channels: Implications for Understanding the Channels in Health and Disease , 2018, Cells.

[118]  Jonathan Downar,et al.  Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial , 2018, The Lancet.

[119]  John Torous,et al.  Characterizing the Clinical Relevance of Digital Phenotyping Data 1 Quality with Applications to a Cohort with Schizophrenia 2 3 , 2018 .

[120]  Brooke R. Staveland,et al.  Intrinsic functional connectivity predicts remission on antidepressants: a randomized controlled trial to identify clinically applicable imaging biomarkers , 2018, Translational Psychiatry.

[121]  K. Narr,et al.  Inflammation and Improvement of Depression Following Electroconvulsive Therapy in Treatment-Resistant Depression. , 2018, The Journal of clinical psychiatry.

[122]  Benjamin G. Shapero,et al.  Ketamine-Associated Brain Changes: A Review of the Neuroimaging Literature , 2018, Harvard review of psychiatry.

[123]  David J. Nutt,et al.  Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression , 2018, Front. Pharmacol..

[124]  Á. Pascual-Leone,et al.  Prospective Validation That Subgenual Connectivity Predicts Antidepressant Efficacy of Transcranial Magnetic Stimulation Sites , 2017, Biological Psychiatry.

[125]  L. Carpenter,et al.  Neuroimaging Mechanisms of Therapeutic Transcranial Magnetic Stimulation for Major Depressive Disorder. , 2017, Biological psychiatry. Cognitive neuroscience and neuroimaging.

[126]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[127]  E. Ballard,et al.  The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. , 2017, The American journal of psychiatry.

[128]  John P. Rice,et al.  Genomic Dissection of Bipolar Disorder and Schizophrenia, Including 28 Subphenotypes , 2017, Cell.

[129]  Justin K. Rajendra,et al.  A connectomic approach for subcallosal cingulate deep brain stimulation surgery: prospective targeting in treatment-resistant depression , 2017, Molecular Psychiatry.

[130]  J. Sheridan,et al.  Microglial recruitment of IL-1β producing monocytes to brain endothelium causes stress-induced anxiety , 2017, Molecular Psychiatry.

[131]  P. Gonzalez-Alegre,et al.  Towards precision medicine , 2017 .

[132]  R. Schmieder,et al.  The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study , 2017, European heart journal.

[133]  Parag G. Patil,et al.  Subcallosal cingulate deep brain stimulation for treatment-resistant depression: a multisite, randomised, sham-controlled trial. , 2017, The lancet. Psychiatry.

[134]  Kevin Murphy,et al.  Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms , 2017, Scientific Reports.

[135]  Cheuk Y. Tang,et al.  Social stress induces neurovascular pathology promoting depression , 2017, Nature Neuroscience.

[136]  Melissa J. Green,et al.  Genome-wide association study identifies 30 Loci Associated with Bipolar Disorder , 2017, bioRxiv.

[137]  L. Kaczmarek,et al.  The need for new approaches in CNS drug discovery: Why drugs have failed, and what can be done to improve outcomes , 2017, Neuropharmacology.

[138]  D. Nutt,et al.  Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition , 2017, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[139]  Helen S Mayberg,et al.  Functional Connectivity of the Subcallosal Cingulate Cortex And Differential Outcomes to Treatment With Cognitive-Behavioral Therapy or Antidepressant Medication for Major Depressive Disorder. , 2017, The American journal of psychiatry.

[140]  B. Nuttin,et al.  Electrical stimulation of the bed nucleus of the stria terminalis reduces anxiety in a rat model , 2017, Translational psychiatry.

[141]  Won Hee Lee,et al.  Addressing reverse inference in psychiatric neuroimaging: Meta‐analyses of task‐related brain activation in common mental disorders , 2017, Human brain mapping.

[142]  Andrew T. Drysdale,et al.  Resting-state connectivity biomarkers define neurophysiological subtypes of depression , 2016, Nature Medicine.

[143]  Thomas E. Nichols,et al.  Scanning the horizon: towards transparent and reproducible neuroimaging research , 2016, Nature Reviews Neuroscience.

[144]  P. Fox,et al.  Altered Brain Activity in Unipolar Depression Revisited: Meta-analyses of Neuroimaging Studies , 2017, JAMA psychiatry.

[145]  D. Goldsmith,et al.  A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression , 2016, Molecular Psychiatry.

[146]  P. Cowen,et al.  Early changes in emotional processing as a marker of clinical response to SSRI treatment in depression , 2016, Translational psychiatry.

[147]  A. Krystal,et al.  Kappa‐Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials , 2016, Depression and anxiety.

[148]  H. Critchley,et al.  A Neurocomputational Account of How Inflammation Enhances Sensitivity to Punishments Versus Rewards , 2016, Biological Psychiatry.

[149]  L. Williams,et al.  Precision psychiatry: a neural circuit taxonomy for depression and anxiety. , 2016, The lancet. Psychiatry.

[150]  Xi-Ping Huang,et al.  NMDAR inhibition-independent antidepressant actions of ketamine metabolites , 2016, Nature.

[151]  Amy L. Salisbury,et al.  Clinical Experience With High-Dosage Pramipexole in Patients With Treatment-Resistant Depressive Episodes in Unipolar and Bipolar Depression. , 2016, The American journal of psychiatry.

[152]  Xiaoping P. Hu,et al.  Inflammation is associated with decreased functional connectivity within corticostriatal reward circuitry in depression , 2015, Molecular Psychiatry.

[153]  Louis-Philippe Morency,et al.  Computational study of psychosis symptoms and facial expressions , 2016 .

[154]  Andrew H. Miller,et al.  The role of inflammation in depression: from evolutionary imperative to modern treatment target , 2015, Nature Reviews Immunology.

[155]  P. Stanton,et al.  The long-lasting antidepressant effects of rapastinel (GLYX-13) are associated with a metaplasticity process in the medial prefrontal cortex and hippocampus , 2015, Neuroscience.

[156]  Anca Velisar,et al.  Beta oscillations in freely moving Parkinson's subjects are attenuated during deep brain stimulation , 2015, Movement disorders : official journal of the Movement Disorder Society.

[157]  H. Mayberg,et al.  Mapping the "Depression Switch" During Intraoperative Testing of Subcallosal Cingulate Deep Brain Stimulation. , 2015, JAMA neurology.

[158]  Christopher S. Poultney,et al.  Insights into Autism Spectrum Disorder Genomic Architecture and Biology from 71 Risk Loci , 2015, Neuron.

[159]  D. Kondziolka,et al.  A Randomized Sham-Controlled Trial of Deep Brain Stimulation of the Ventral Capsule/Ventral Striatum for Chronic Treatment-Resistant Depression , 2015, Biological Psychiatry.

[160]  A. Khajavi,et al.  Burden of Hepatitis C in Iran Between 1990 and 2010: findings from the Global Burden of Disease Study 2010. , 2015, Archives of Iranian medicine.

[161]  Jens Kuhn,et al.  Deep Brain Stimulation for Obsessive-Compulsive Disorder: A Meta-Analysis of Treatment Outcome and Predictors of Response , 2015, PloS one.

[162]  R. Yuste.  From the neuron doctrine to neural networks , 2015, Nature Reviews Neuroscience.

[163]  J. O'reardon,et al.  Efficacy and Safety of Low-field Synchronized Transcranial Magnetic Stimulation (sTMS) for Treatment of Major Depression , 2015, Brain Stimulation.

[164]  C. Hamani,et al.  High‐frequency stimulation of the medial prefrontal cortex decreases cellular firing in the dorsal raphe , 2015, The European journal of neuroscience.

[165]  P. Fox,et al.  Identification of a common neurobiological substrate for mental illness. , 2015, JAMA psychiatry.

[166]  L. Williams,et al.  Amygdala Reactivity to Emotional Faces in the Prediction of General and Medication-Specific Responses to Antidepressant Treatment in the Randomized iSPOT-D Trial , 2015, Neuropsychopharmacology.

[167]  Y. Temel,et al.  Electrical stimulation alleviates depressive-like behaviors of rats: investigation of brain targets and potential mechanisms , 2015, Translational Psychiatry.

[168]  Y. Temel,et al.  The antidepressant effects of ventromedial prefrontal cortex stimulation is associated with neural activation in the medial part of the subthalamic nucleus , 2015, Behavioural Brain Research.

[169]  G. Dichter,et al.  A systematic review of relations between resting-state functional-MRI and treatment response in major depressive disorder. , 2015, Journal of affective disorders.

[170]  Shannon M. Pruden,et al.  A Meta-analysis of Neuroimaging Studies , 2015 .

[171]  A. Schatzberg,et al.  Ketamine: Promising Path or False Prophecy in the Development of Novel Therapeutics for Mood Disorders? , 2015, Neuropsychopharmacology.

[172]  E J Costello,et al.  A heavy burden on young minds: the global burden of mental and substance use disorders in children and youth , 2014, Psychological Medicine.

[173]  Justin K. Rajendra,et al.  Defining Critical White Matter Pathways Mediating Successful Subcallosal Cingulate Deep Brain Stimulation for Treatment-Resistant Depression , 2014, Biological Psychiatry.

[174]  K. Bujarski,et al.  Exploring emotions using invasive methods: review of 60 years of human intracranial electrophysiology. , 2014, Social cognitive and affective neuroscience.

[175]  Boris Yamrom,et al.  The contribution of de novo coding mutations to autism spectrum disorder , 2014, Nature.

[176]  Christopher S. Poultney,et al.  Synaptic, transcriptional, and chromatin genes disrupted in autism , 2014, Nature.

[177]  Conor Liston,et al.  Default Mode Network Mechanisms of Transcranial Magnetic Stimulation in Depression , 2014, Biological Psychiatry.

[178]  Simon B Eickhoff,et al.  Meta-analysis in human neuroimaging: computational modeling of large-scale databases. , 2014, Annual review of neuroscience.

[179]  J. Sheridan,et al.  Re-establishment of Anxiety in Stress-Sensitized Mice Is Caused by Monocyte Trafficking from the Spleen to the Brain , 2014, Biological Psychiatry.

[180]  Sarah H. Lisanby,et al.  Coil design considerations for deep transcranial magnetic stimulation , 2014, Clinical Neurophysiology.

[181]  Michael K Parides,et al.  Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. , 2014, JAMA psychiatry.

[182]  C. Reynolds,et al.  Resting state functional connectivity and treatment response in late-life depression , 2013, Psychiatry Research: Neuroimaging.

[183]  T. Ketter,et al.  Assessing efficacy/effectiveness and safety/tolerability profiles of adjunctive pramipexole in bipolar depression: acute versus long-term data , 2013, International clinical psychopharmacology.

[184]  K. Deisseroth,et al.  Optogenetics , 2013, Proceedings of the National Academy of Sciences.

[185]  L. Kegeles,et al.  Randomized Controlled Crossover Trial of Ketamine in Obsessive-Compulsive Disorder: Proof-of-Concept , 2013, Neuropsychopharmacology.

[186]  D. F. Drake,et al.  Chronic Interferon-α Decreases Dopamine 2 Receptor Binding and Striatal Dopamine Release in Association with Anhedonia-Like Behavior in Nonhuman Primates , 2013, Neuropsychopharmacology.

[187]  B. Bradley,et al.  Childhood maltreatment is associated with distinct genomic and epigenetic profiles in posttraumatic stress disorder , 2013, Proceedings of the National Academy of Sciences.

[188]  Bradley S Peterson,et al.  Antidepressants normalize the default mode network in patients with dysthymia. , 2013, JAMA psychiatry.

[189]  L. Williams,et al.  Using Standardized fMRI Protocols to Identify Patterns of Prefrontal Circuit Dysregulation that are Common and Specific to Cognitive and Emotional Tasks in Major Depressive Disorder: First Wave Results from the iSPOT-D Study , 2013, Neuropsychopharmacology.

[190]  D. F. Drake,et al.  Dopaminergic mechanisms of reduced basal ganglia responses to hedonic reward during interferon alfa administration. , 2012, Archives of general psychiatry.

[191]  G. Dichter,et al.  Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings , 2012, Journal of Neurodevelopmental Disorders.

[192]  Michael F. Walker,et al.  De novo mutations revealed by whole-exome sequencing are strongly associated with autism , 2012, Nature.

[193]  Evan T. Geller,et al.  Patterns and rates of exonic de novo mutations in autism spectrum disorders , 2012, Nature.

[194]  A. Schene,et al.  Successful pharmacologic treatment of major depressive disorder attenuates amygdala activation to negative facial expressions: a functional magnetic resonance imaging study. , 2012, The Journal of clinical psychiatry.

[195]  Caroline F. Zink,et al.  Human neuroimaging of oxytocin and vasopressin in social cognition , 2012, Hormones and Behavior.

[196]  Bradley P. Coe,et al.  Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations , 2012, Nature.

[197]  Megan M. Filkowski,et al.  Subcallosal cingulate deep brain stimulation for treatment-resistant unipolar and bipolar depression. , 2012, Archives of general psychiatry.

[198]  N. Logothetis,et al.  Direct electrical stimulation of human cortex — the gold standard for mapping brain functions? , 2011, Nature Reviews Neuroscience.

[199]  内田隆一,et al.  小児急性嘔吐下痢症に対する五苓散の効果:バングラデシュにおけるRandomized,Double‐blind,Controlled Trial , 2012 .

[200]  Manuel A. R. Ferreira,et al.  Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4 , 2011, Nature Genetics.

[201]  Boris Yamrom,et al.  Rare De Novo and Transmitted Copy-Number Variation in Autistic Spectrum Disorders , 2011, Neuron.

[202]  Kathryn Roeder,et al.  Multiple Recurrent De Novo CNVs, Including Duplications of the 7q11.23 Williams Syndrome Region, Are Strongly Associated with Autism , 2011, Neuron.

[203]  T. Münte,et al.  Pramipexole modulates the neural network of reward anticipation , 2011, Human brain mapping.

[204]  D. Bowers,et al.  Smile and laughter induction and intraoperative predictors of response to deep brain stimulation for obsessive-compulsive disorder , 2011, NeuroImage.

[205]  D. Zald,et al.  Reconsidering anhedonia in depression: Lessons from translational neuroscience , 2011, Neuroscience & Biobehavioral Reviews.

[206]  Chen,et al.  A functional magnetic resonance imaging study , 2011 .

[207]  Elliot T. Berkman,et al.  Inflammation-Induced Anhedonia: Endotoxin Reduces Ventral Striatum Responses to Reward , 2010, Biological Psychiatry.

[208]  T. Insel,et al.  Wesleyan University From the SelectedWorks of Charles A . Sanislow , Ph . D . 2010 Research Domain Criteria ( RDoC ) : Toward a New Classification Framework for Research on Mental Disorders , 2018 .

[209]  M. Gerritsen,et al.  Current Challenges and Future Directions , 2010 .

[210]  A. Bruijnzeel.  kappa-Opioid receptor signaling and brain reward function , 2009, Brain Research Reviews.

[211]  H. Critchley,et al.  Inflammation Causes Mood Changes Through Alterations in Subgenual Cingulate Activity and Mesolimbic Connectivity , 2009, Biological Psychiatry.

[212]  H. Critchley,et al.  Neural Origins of Human Sickness in Interoceptive Responses to Inflammation , 2009, Biological Psychiatry.

[213]  A. Bailey,et al.  Are there theory of mind regions in the brain? A review of the neuroimaging literature , 2009, Human brain mapping.

[214]  D. Javitt.  Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modification. , 2009, Current opinion in drug discovery & development.

[215]  O. Sporns,et al.  Complex brain networks: graph theoretical analysis of structural and functional systems , 2009, Nature Reviews Neuroscience.

[216]  S. Rauch,et al.  Deep Brain Stimulation of the Ventral Capsule/Ventral Striatum for Treatment-Resistant Depression , 2009, Biological Psychiatry.

[217]  Melanie Volkamer,et al.  Proof of Concept , 2009 .

[218]  F. Schmidt.  Meta-Analysis , 2008 .

[219]  Cesar Augusto Guevara-Cuellar,et al.  Electroconvulsive therapy for depression. , 2008, The New England journal of medicine.

[220]  R. Dantzer,et al.  From inflammation to sickness and depression: when the immune system subjugates the brain , 2008, Nature Reviews Neuroscience.

[221]  Kenny Q. Ye,et al.  Strong Association of De Novo Copy Number Mutations with Autism , 2007, Science.

[222]  N. Atasoy,et al.  Plasma Levels of Tumor Necrosis Factor-Alpha and Interleukin-6 in Obsessive Compulsive Disorder , 2007, Mediators of inflammation.

[223]  Paul J Carlson,et al.  A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. , 2006, Archives of general psychiatry.

[224]  D. Luckenbaugh,et al.  A double-blind, placebo-controlled study of memantine in the treatment of major depression. , 2006, The American journal of psychiatry.

[225]  K. Deisseroth,et al.  Millisecond-timescale, genetically targeted optical control of neural activity , 2005, Nature Neuroscience.

[226]  A. Lozano,et al.  Deep Brain Stimulation for Treatment-Resistant Depression , 2005, Neuron.

[227]  M. Burns,et al.  Case-Control Study , 2020, Definitions.

[228]  A. Rush,et al.  Speed of response and remission in major depressive disorder with acute electroconvulsive therapy (ECT): a Consortium for Research in ECT (CORE) report. , 2004, The Journal of clinical psychiatry.

[229]  C. Baird,et al.  The pilot study. , 2000, Orthopedic nursing.

[230]  Vir V. Phoha,et al.  Viewpoint , 1999, CACM.

[231]  J. Broadhead,et al.  WHO consensus statement. , 1990, The British journal of psychiatry : the journal of mental science.

[232]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[233]  N. Sobol,et al.  PRELIMINARY RESULTS , 2004 .

[234]  E. Glaser.  The randomized clinical trial. , 1972, The New England journal of medicine.

[235]  M. Uslenghi,et al.  The World Space Observatory (WSO-UV) - Current status , 2008, 0801.2080.

[236]  W. Penfield,et al.  SOMATIC MOTOR AND SENSORY REPRESENTATION IN THE CEREBRAL CORTEX OF MAN AS STUDIED BY ELECTRICAL STIMULATION , 1937 .